Fertility Enhancing Treatment - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB504240819

Publication Date:

April 3, 2024

Pages:

103

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Infertility Drugs are drugs which enhance reproductive fertility. For women, Infertility Drugs is used to stimulate follicle development of the ovary. Agents that enhance ovarian activity can be classified as either Gonadotropin releasing hormone, Estrogen antagonists or Gonadotropins.
The global market for Fertility Enhancing Treatment was estimated to be worth US$ 4949 million in 2023 and is forecast to a readjusted size of US$ 7577.7 million by 2030 with a CAGR of 6.2% during the forecast period 2024-2030
Global Fertility Enhancing Treatment key players include Merck, Ferring, MSD, LIVZON, Abbott, etc. Global top five manufacturers hold a share about 60%.
North America is the largest market, with a share over 30%, followed by China, and Europe, both have a share about 40 percent.
In terms of product, Fertility Drugs for Women is the largest segment, with a share over 85%. And in terms of application, the largest application is Drug Stores, followed by Hospitals, Online, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Fertility Enhancing Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Fertility Enhancing Treatment by region & country, by Type, and by Application.
The Fertility Enhancing Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fertility Enhancing Treatment.
麻豆原创 Segmentation
By Company
Merck
Ferring
MSD
LIVZON
Abbott
Bayer Zydus Pharma
颁丑耻谤肠丑锛咲飞颈驳丑迟
SASMAR
BioFilm,Inc
FAIRHAVEN HEALTH
The YES YES Company
Segment by Type:
Fertility Drugs for Women
Fertility Drugs for Men
OTC Conception Gels/Lubricants
Segment by Application
Hospitals
Drug Stores
Online
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Fertility Enhancing Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Fertility Enhancing Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Fertility Enhancing Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Fertility Enhancing Treatment Product Introduction
1.2 Global Fertility Enhancing Treatment 麻豆原创 Size Forecast
1.3 Fertility Enhancing Treatment 麻豆原创 Trends & Drivers
1.3.1 Fertility Enhancing Treatment Industry Trends
1.3.2 Fertility Enhancing Treatment 麻豆原创 Drivers & Opportunity
1.3.3 Fertility Enhancing Treatment 麻豆原创 Challenges
1.3.4 Fertility Enhancing Treatment 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Fertility Enhancing Treatment Players Revenue Ranking (2023)
2.2 Global Fertility Enhancing Treatment Revenue by Company (2019-2024)
2.3 Key Companies Fertility Enhancing Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Fertility Enhancing Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Fertility Enhancing Treatment
2.6 Fertility Enhancing Treatment 麻豆原创 Competitive Analysis
2.6.1 Fertility Enhancing Treatment 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Fertility Enhancing Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fertility Enhancing Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Fertility Drugs for Women
3.1.2 Fertility Drugs for Men
3.1.3 OTC Conception Gels/Lubricants
3.2 Global Fertility Enhancing Treatment Sales Value by Type
3.2.1 Global Fertility Enhancing Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Fertility Enhancing Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Fertility Enhancing Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Drug Stores
4.1.3 Online
4.2 Global Fertility Enhancing Treatment Sales Value by Application
4.2.1 Global Fertility Enhancing Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Fertility Enhancing Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Fertility Enhancing Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Fertility Enhancing Treatment Sales Value by Region
5.1.1 Global Fertility Enhancing Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Fertility Enhancing Treatment Sales Value by Region (2019-2024)
5.1.3 Global Fertility Enhancing Treatment Sales Value by Region (2025-2030)
5.1.4 Global Fertility Enhancing Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Fertility Enhancing Treatment Sales Value, 2019-2030
5.2.2 North America Fertility Enhancing Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Fertility Enhancing Treatment Sales Value, 2019-2030
5.3.2 Europe Fertility Enhancing Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Fertility Enhancing Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Fertility Enhancing Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Fertility Enhancing Treatment Sales Value, 2019-2030
5.5.2 South America Fertility Enhancing Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Fertility Enhancing Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Fertility Enhancing Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Fertility Enhancing Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Fertility Enhancing Treatment Sales Value
6.3 United States
6.3.1 United States Fertility Enhancing Treatment Sales Value, 2019-2030
6.3.2 United States Fertility Enhancing Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Fertility Enhancing Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Fertility Enhancing Treatment Sales Value, 2019-2030
6.4.2 Europe Fertility Enhancing Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Fertility Enhancing Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Fertility Enhancing Treatment Sales Value, 2019-2030
6.5.2 China Fertility Enhancing Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Fertility Enhancing Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Fertility Enhancing Treatment Sales Value, 2019-2030
6.6.2 Japan Fertility Enhancing Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Fertility Enhancing Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Fertility Enhancing Treatment Sales Value, 2019-2030
6.7.2 South Korea Fertility Enhancing Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Fertility Enhancing Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Fertility Enhancing Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Fertility Enhancing Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Fertility Enhancing Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Fertility Enhancing Treatment Sales Value, 2019-2030
6.9.2 India Fertility Enhancing Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Fertility Enhancing Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Merck
7.1.1 Merck Profile
7.1.2 Merck Main Business
7.1.3 Merck Fertility Enhancing Treatment Products, Services and Solutions
7.1.4 Merck Fertility Enhancing Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Merck Recent Developments
7.2 Ferring
7.2.1 Ferring Profile
7.2.2 Ferring Main Business
7.2.3 Ferring Fertility Enhancing Treatment Products, Services and Solutions
7.2.4 Ferring Fertility Enhancing Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Ferring Recent Developments
7.3 MSD
7.3.1 MSD Profile
7.3.2 MSD Main Business
7.3.3 MSD Fertility Enhancing Treatment Products, Services and Solutions
7.3.4 MSD Fertility Enhancing Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 LIVZON Recent Developments
7.4 LIVZON
7.4.1 LIVZON Profile
7.4.2 LIVZON Main Business
7.4.3 LIVZON Fertility Enhancing Treatment Products, Services and Solutions
7.4.4 LIVZON Fertility Enhancing Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 LIVZON Recent Developments
7.5 Abbott
7.5.1 Abbott Profile
7.5.2 Abbott Main Business
7.5.3 Abbott Fertility Enhancing Treatment Products, Services and Solutions
7.5.4 Abbott Fertility Enhancing Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Abbott Recent Developments
7.6 Bayer Zydus Pharma
7.6.1 Bayer Zydus Pharma Profile
7.6.2 Bayer Zydus Pharma Main Business
7.6.3 Bayer Zydus Pharma Fertility Enhancing Treatment Products, Services and Solutions
7.6.4 Bayer Zydus Pharma Fertility Enhancing Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Bayer Zydus Pharma Recent Developments
7.7 颁丑耻谤肠丑锛咲飞颈驳丑迟
7.7.1 颁丑耻谤肠丑锛咲飞颈驳丑迟 Profile
7.7.2 颁丑耻谤肠丑锛咲飞颈驳丑迟 Main Business
7.7.3 颁丑耻谤肠丑锛咲飞颈驳丑迟 Fertility Enhancing Treatment Products, Services and Solutions
7.7.4 颁丑耻谤肠丑锛咲飞颈驳丑迟 Fertility Enhancing Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 颁丑耻谤肠丑锛咲飞颈驳丑迟 Recent Developments
7.8 SASMAR
7.8.1 SASMAR Profile
7.8.2 SASMAR Main Business
7.8.3 SASMAR Fertility Enhancing Treatment Products, Services and Solutions
7.8.4 SASMAR Fertility Enhancing Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 SASMAR Recent Developments
7.9 BioFilm,Inc
7.9.1 BioFilm,Inc Profile
7.9.2 BioFilm,Inc Main Business
7.9.3 BioFilm,Inc Fertility Enhancing Treatment Products, Services and Solutions
7.9.4 BioFilm,Inc Fertility Enhancing Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 BioFilm,Inc Recent Developments
7.10 FAIRHAVEN HEALTH
7.10.1 FAIRHAVEN HEALTH Profile
7.10.2 FAIRHAVEN HEALTH Main Business
7.10.3 FAIRHAVEN HEALTH Fertility Enhancing Treatment Products, Services and Solutions
7.10.4 FAIRHAVEN HEALTH Fertility Enhancing Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 FAIRHAVEN HEALTH Recent Developments
7.11 The YES YES Company
7.11.1 The YES YES Company Profile
7.11.2 The YES YES Company Main Business
7.11.3 The YES YES Company Fertility Enhancing Treatment Products, Services and Solutions
7.11.4 The YES YES Company Fertility Enhancing Treatment Revenue (US$ Million) & (2019-2024)
7.11.5 The YES YES Company Recent Developments
8 Industry Chain Analysis
8.1 Fertility Enhancing Treatment Industrial Chain
8.2 Fertility Enhancing Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Fertility Enhancing Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Fertility Enhancing Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Merck
Ferring
MSD
LIVZON
Abbott
Bayer Zydus Pharma
颁丑耻谤肠丑锛咲飞颈驳丑迟
SASMAR
BioFilm,Inc
FAIRHAVEN HEALTH
The YES YES Company

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.